US Patent Issued to Orionis Biosciences, Orionis Biosciences, VIB VZW, Universiteit Gent on Feb. 10 for "Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes" (Belgian, American Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,426, issued on Feb. 10, was assigned to Orionis Biosciences Inc. (Waltham, Mass.), Orionis Biosciences BV (Zwijnaarde, Belgium), VIB VZW (Ghent, Belgium) and Universiteit Gent (Ghent, Belgium).

"Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes" was invented by Nikolai Kley (Waltham, Mass.), Jan Tavernier (Zwijnaarde, Belgium) and Leander Huyghe (Beernem, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-Gamma) and methods of tre...